7/22/2013

Watertown, Mass.-based biotech pSivida secured $10.8 million from a public stock offering. According to an SEC filing, the money will support further clinical development of Iluvien, an experimental drug for posterior uveitis, and fund pSivida's other research and development programs.

Related Summaries